全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 329773-35-5 |
|---|---|---|---|
| 分子式 | C36H39NO5 | 纯度 | 98% |
| 分子量 | 565.7 | 货号 | abs47027876 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | is the first of a new class of soluble g | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Cinaciguat 329773-35-5
| 产品描述 | |
| 描述 | Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure. |
| 纯度 | 98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| 靶点 | Guanylate Cyclase |
| In vitro(体外研究) | Cinaciguat (10 μM) significantly enhances intracellular cGMP generation. Cinaciguat does not dose-dependent effects on cell contraction and calcium transients. |
| In vivo(体内研究) | Cinaciguat (10 mg/kg/day, p.o.) treatment in diabetic rats does not influence blood glucose levels, but leads to attenuated water intake. Cinaciguat treatment alleviates diabetes mellitus related oxidative stress, protects against DM related alteration of the NO-sGC-cGMP-PKG signalling, and alleviates DM related myocardium hypertrophy and apoptosis. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not have any effect on phasic activity induced by PGF2α in WT or apo-sGC strips. |
| 参考文献 | |
| 参考文献 |
|
| 研究领域 | |
| 研究领域 | Signal TransductionProtein PhosphorylationSer / Thr KinasesOther Kinases Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：